CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy

Ovarian cancer and triple-negative breast cancer (TNBC) are among the most lethal diseases affecting women, with few targeted therapies and high rates of metastasis. Here we show that CD24 can be the dominant innate immune checkpoint in ovarian cancer and breast cancer, and is a new, promising targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Barkal, Amira A, Brewer, Rachel E., Markovic, Maxim, Kowarsky, Mark, Barkal, Sammy A, Zaro, Balyn W., Krishnan, Venkatesh, Hatakeyama, Jason, Dorigo, Oliver, Barkal, Layla J, Weissman, Irving L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697206/
https://www.ncbi.nlm.nih.gov/pubmed/31367043
http://dx.doi.org/10.1038/s41586-019-1456-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697206/
https://www.ncbi.nlm.nih.gov/pubmed/31367043
http://dx.doi.org/10.1038/s41586-019-1456-0

Ejemplares similares